Partial
Partially Aligned
Patient Risk:
Low
Summary
Partially aligned with the label on indication and general topical use, but several statements about symptom timelines, image-based response descriptions, and use for ongoing flare control are not supported by the provided prescribing information excerpts.
Category Scores
Accurate Statements
Eucrisa (crisaborole) is a topical medication for certain forms of eczema (atopic dermatitis).
Label Indications: topical treatment of mild to moderate atopic dermatitis (Section 1).
Eucrisa is indicated for mild-to-moderate atopic dermatitis in certain age groups.
Label Indications: adult and pediatric patients 3 months of age and older (Section 1).
Unsupported Statements
Eucrisa treatment response is usually described using symptom scores (for example, itch and rash signs), not dramatic “before/after” photographs.
Provided label excerpts do not discuss how treatment response is typically described or whether photographs vs symptom scores are used.
When people see improvement with Eucrisa, it is typically reflected as less redness and inflammation in the affected area.
Label excerpt provided does not specify expected clinical response description (e.g., redness/inflammation).
When people see improvement with Eucrisa, it is typically reflected as reduced itching.
Label excerpt provided does not specify that itch reduction is the described outcome for response.
With Eucrisa, improvements that build over days to weeks rather than changing instantly are typically described.
The label excerpt provides trial durations (28 days; 52 weeks for once-daily trial) but does not state a typical onset pattern (days vs weeks) or that changes are not instant.
Eucrisa is designed for short-term symptom relief and ongoing control of eczema flares.
Provided label excerpts do not describe the product as designed for short-term relief or ongoing flare control.
Exact timelines for Eucrisa to work can vary depending on severity and body location.
Provided label excerpts do not provide such timing variability factors.
Exact timelines for Eucrisa to work can vary depending on how consistently it is applied.
Provided label excerpts do not link onset/timelines to adherence/consistency effects.
Exact timelines for Eucrisa to work can vary depending on skin irritation triggers.
Provided label excerpts do not state onset/timeline variation based on skin irritation triggers.
Contradictions
Important Omissions
Dosage instructions (apply a thin layer twice daily; consider reducing to once daily once clinical effect is achieved) and topical-use-only restriction (not ophthalmic/oral/intravaginal).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response does not include contraindications, hypersensitivity, or specific safety warnings; however, the unsupported statements are primarily about expected response/timing and do not directly conflict with safety information in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims about how improvement is typically reflected (redness/inflammation, itching), typical onset pattern, and determinants of response timelines are not supported by the provided label excerpts. The response also omits key administration details (twice daily thin layer; consider once daily after clinical effect; topical-only restrictions).
Suggested Improvement
Limit statements to label-supported items: indication (mild to moderate atopic dermatitis, age ≥3 months), topical use and dosing frequency (twice daily thin layer; consider once daily after clinical effect), and known safety information from label (contraindication/hypersensitivity reactions prompting discontinuation). Avoid describing typical response timing or outcome framing unless the label excerpts explicitly support it.